- RBD is a parasomnia of dream enactment caused by loss of normal REM sleep atonia.
- RBD is strongly associated with α-synuclein-related neurodegenerative disorders and recognised as an early biomarker of neurodegeneration.
- Management prioritises safety and symptomatic control while trials explore disease-modifying therapies and RBD's role in neuroprotective research.
Neurol Clin. 2027 Feb;45(1):117-132. doi: 10.1016/j.ncl.2026.07.008. Epub 2026 Oct 15.
ABSTRACT
Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia characterized by dream enactment behaviors resulting from loss of normal REM sleep atonia. Increasingly, RBD is recognized not only as a sleep disorder but as a critical neurologic entity, strongly associated with α-synuclein-related neurodegenerative diseases This review highlights recent advances in the understanding of RBD across its clinical spectrum, diagnosis, pathophysiology, and emerging role as a biomarker of neurodegeneration. Current management focuses on safety and symptomatic control, while ongoing research explores disease-modifying therapies and positions RBD as a key platform for neuroprotective clinical trials.
PMID:43045430 | DOI:10.1016/j.ncl.2026.07.008
Share Evidence Blueprint
Save to Google Notes

Search Google Scholar
⭐ My Revision List

